Denali Therapeutics falls as ALS drug fails to meet main goal in mid-stage study

Denali Therapeutics

16/02/2024 13:46

** Shares of drug developer Denali Therapeutics  DNLI.O 
fall 6% to $17.25 premarket
    ** Co's neurological disease drug being developed with
partner Sanofi  SASY.PA   did not meet the main goal of a
mid-stage study 
     ** The drug is being tested to potentially treat
Amyotrophic lateral sclerosis (ALS) a disease that affects nerve
cells in the brain and spinal cord
    ** Co says Sanofi will continue to conduct a mid-stage trial
testing the drug in patients with multiple sclerosis, a disease
of the central nervous system
    ** Stock fell 37.9% in the last 12 months 

 (Reporting by Sneha  S K)
 ((Sneha.SK@thomsonreuters.com;))